Rivastigmine Patch, Extended Release
Product Images NDC 70710-1196

21 FDA label images from Zydus Pharmaceuticals Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 70710-1196). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 01)

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 01)
Chemical structure of rivastigmine, displaying its molecular configuration with functional groups and carbon ring bonds as depicted in the diagram.*
FDA Label Image

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 02)

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 02)
An illustration showing a cross-section diagram of a transdermal patch labeled with four distinct layers: Layer 1, Layer 2, Layer 3, and Layer 4. Each layer is visually differentiated by varying patterns, representing the layered structure of a drug delivery patch.*
FDA Label Image

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 03)

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 03)
A line graph depicting rivastigmine plasma concentration (ng/mL) over 24 hours for three extended-release transdermal patch strengths: 13.3 mg/24h, 9.5 mg/24h, and 4.6 mg/24h. The x-axis shows time in hours, and the y-axis shows rivastigmine concentration. Data points for each strength demonstrate peak and decline trends with error bars.*
FDA Label Image

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 04)

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 04)
A line graph showing least square mean changes from baseline ADAS-Cog ratings over 24 weeks during treatment with rivastigmine and placebo. Four groups are compared: 17.4 mg/24 hours patch, 9.5 mg/24 hours patch, 6 mg capsules twice daily, and placebo. The y-axis indicates clinical improvement and decline, while the x-axis shows time in weeks. Error bars represent standard error of mean (SEM).*
FDA Label Image

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 05)

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 05)
A bar chart displaying the percentage of patients by ADCS-CGIC rating categories, including Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse. The chart compares four treatment groups: Rivastigmine patch 17.4 mg/24 hours, Rivastigmine patch 9.5 mg/24 hours, Capsules 6 mg BID, and Placebo, illustrating patient response distributions across these categories.*
FDA Label Image

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 06)

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 06)
A line graph showing ADCI-ADL change from baseline over 48 weeks of treatment for Rivastigmine Transdermal System at 13.3 mg/24 hr and 9.5 mg/24 hr doses. The Y-axis represents change scores with clinical improvement at the top and clinical decline at the bottom. Two lines plot the data with error bars, indicating greater clinical decline over time, more pronounced in the 9.5 mg/24 hr group. Points marked with 'x' denote statistically significant differences between doses.*
FDA Label Image

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 07)

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 07)
A line graph showing the ADAS-Cog change from baseline (LS means and SEM) over 48 weeks of treatment comparing Rivastigmine Transdermal System 13.3 mg/24 hr and 9.5 mg/24 hr. The y-axis represents cognitive change with clinical improvement at the top and clinical decline at the bottom. The 13.3 mg/24 hr dose demonstrates less cognitive decline compared to the 9.5 mg/24 hr dose over time.*
FDA Label Image

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 08)

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 08)
A line graph comparing the least squares mean change over 24 weeks of treatment for Rivastigmine Transdermal System 13.3 mg/24 hr and 4.6 mg/24 hr. The y-axis measures LS mean change with standard errors, indicating clinical improvement or decline. The 13.3 mg/24 hr dose shows lesser decline and statistically significant improvement at 16 and 24 weeks compared to the 4.6 mg/24 hr dose.*
FDA Label Image

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 09)

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 09)
A line graph comparing the least squares mean change plus/minus standard errors (LS means ± STE) in response to Rivastigmine Transdermal System 13.3 mg/24 hr and 4.6 mg/24 hr over 0, 8, 16, and 24 weeks of treatment. The graph plots clinical improvement versus clinical decline on the y-axis, showing statistically significant differences at weeks 16 and 24 for the 13.3 mg/24 hr dose compared to 4.6 mg/24 hr. Data is based on an analysis of covariance model adjusted for pooled center and baseline.*
FDA Label Image

Figure A (F5859f1d 1a9a 4576 B177 12d8c0fa770e 10)

Figure A (F5859f1d 1a9a 4576 B177 12d8c0fa770e 10)
An instructional diagram showing the Rivastigmine Transdermal System packaged in a pouch labeled with product and manufacturer information. The patch is round with protective liners on both sides, an adhesive layer containing medicine, and an outside backing. Arrows indicate the pouch opening, patch components, and protective layers.*
FDA Label Image

Figure B (F5859f1d 1a9a 4576 B177 12d8c0fa770e 11)

Figure B (F5859f1d 1a9a 4576 B177 12d8c0fa770e 11)
Illustration showing recommended application sites for Rivastigmine transdermal patches on the human body. The diagram depicts the left or right upper arm (side view), left or right side of the chest (front and back views), left or right upper back, and left or right lower back areas with shaded squares indicating placement zones.*
FDA Label Image

Figure C (F5859f1d 1a9a 4576 B177 12d8c0fa770e 12)

Figure C (F5859f1d 1a9a 4576 B177 12d8c0fa770e 12)
An instructional illustration showing a hand holding a Rivastigmine Transdermal System pouch, positioned for opening with scissors. The pouch indicates it contains one transdermal system patch for extended-release delivery, labeled for Rx use only by Zydus Pharmaceuticals USA Inc.*
FDA Label Image

Figure D (F5859f1d 1a9a 4576 B177 12d8c0fa770e 13)

Figure D (F5859f1d 1a9a 4576 B177 12d8c0fa770e 13)
An instructional illustration showing two hands peeling open the protective backing of a circular transdermal patch, likely representing the Rivastigmine extended-release patch used for transdermal application.*
FDA Label Image

Figure E (F5859f1d 1a9a 4576 B177 12d8c0fa770e 14)

Figure E (F5859f1d 1a9a 4576 B177 12d8c0fa770e 14)
An instructional illustration showing the handling of a Rivastigmine transdermal patch, extended release. The image depicts two hands peeling protective liners from the sticky surface of the circular patch before applying it to the skin.*
FDA Label Image

Figure F (F5859f1d 1a9a 4576 B177 12d8c0fa770e 15)

Figure F (F5859f1d 1a9a 4576 B177 12d8c0fa770e 15)
An instructional illustration showing the application of a transdermal patch on the upper back, near the shoulder blade. Two hands are depicted, one holding the patch in place while the other peels back the protective layer from the patch. This image relates to the use of Rivastigmine extended-release transdermal patches.*
FDA Label Image

Figure G (F5859f1d 1a9a 4576 B177 12d8c0fa770e 16)

Figure G (F5859f1d 1a9a 4576 B177 12d8c0fa770e 16)
Illustration showing the back of a person with a hand reaching to apply or remove a transdermal patch along the upper back near the shoulder blade. This likely demonstrates the proper placement or handling of a Rivastigmine transdermal patch.*
FDA Label Image

Figure H (F5859f1d 1a9a 4576 B177 12d8c0fa770e 17)

Figure H (F5859f1d 1a9a 4576 B177 12d8c0fa770e 17)
An instructional illustration showing the application of a transdermal patch on the upper chest area. One hand holds and removes the backing from the patch, while the other hand presses the patch onto the skin, indicating proper placement and adhesion technique for the Rivastigmine extended-release patch.*
FDA Label Image

Figure I (F5859f1d 1a9a 4576 B177 12d8c0fa770e 18)

Figure I (F5859f1d 1a9a 4576 B177 12d8c0fa770e 18)
Instructional illustration showing proper disposal of a Rivastigmine transdermal patch. It depicts folding the sticky sides of the patch together, sliding the folded patch into an empty pouch, and placing the pouch into trash while keeping it away from children and pets.*
FDA Label Image

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 19)

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 19)
Box label for Rivastigmine Transdermal System 4.6 mg/24 hours patch by Zydus Pharmaceuticals USA Inc. The label states it contains 30 systems for transdermal use only. It includes directions for discarding used patches, storage instructions, and caution to keep out of reach of children. Manufacturer information shows Zydus Lifesciences Ltd. in India with distribution by Zydus Pharmaceuticals (USA) Inc.*
FDA Label Image

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 20)

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 20)
Packaging label for Rivastigmine Transdermal System 9.5 mg/24 hours, a prescription patch for transdermal use. The label states the box contains 30 systems and includes manufacturer information for Zydus Lifesciences Ltd and distributor details for Zydus Pharmaceuticals USA Inc. It provides basic usage and storage instructions, warnings to keep out of reach of children, and disposal instructions for used patches. The label also displays the NDC 70710-1197-7.*
FDA Label Image

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 21)

Rivastigmine Transdermal System (F5859f1d 1a9a 4576 B177 12d8c0fa770e 21)
Packaging label for Rivastigmine Transdermal System patch delivering 13.3 mg/24 hours, manufactured and distributed by Zydus Pharmaceuticals USA Inc. The label shows that the package contains 30 transdermal systems for extended-release transdermal use only. It includes usage instruction to remove and discard patches every 24 hours, storage conditions, and safety warnings, along with the NDC number 70710-1198-7.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.